First human test of novel Cancer-Fighting drug begins
NCT ID NCT07181681
Summary
This is a first-in-human study to test the safety and find the right dose of a new experimental drug called BG-C0902 for people with advanced solid tumors. The drug is designed to target two specific proteins found on some cancer cells. Researchers will enroll about 63 participants to see how the body handles the drug and to look for early signs that it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Monash Health
RECRUITINGClayton, Victoria, VIC 3168, Australia
-
Next Oncology
RECRUITINGSan Antonio, Texas, 78229-6028, United States
-
Next Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, Fujian, 361003, China
-
The University of Texas Md Anderson Cancer Center
RECRUITINGHouston, Texas, 77030-4009, United States
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.